HK Stock Market Alert | Laekna Pharma-B (02105) Rises Nearly 15% Before Midday as Exclusive Licensing Agreement for LAE118 Advances; Receives Upfront Payment from Vasque Bio

Lai Kai Medicine-B (02105) rose nearly 15% in the morning session. As of this report, it was up 14.63% at HK$7.13, with a trading volume of HK$9.0682 million.

Zhitong FinanceJun 28 23:53 ET

Tirzepatide, in combination with LAE102 from Laekna Pharma-B (02105), is driving innovation in a 'China solution' for muscle gain and fat loss.

This investigator-initiated trial (IIT), combining LAE102 with tirzepatide, aims to explore a next-generation combination therapy that could deliver more effective long-term benefits for patients with obesity, driving continuous innovation of the 'China solution' to address the significant and currently unmet need for 'increasing muscle mass while reducing fat.'

Zhitong FinanceJun 28 20:32 ET

Hong Kong Stock Ratings Summary: Guohai Securities Maintains BUY Rating on MINIMAX

Cailian Press will regularly compile ratings and target prices from various institutions for Hong Kong stocks.

cls.cnJun 18 03:06 ET

Guotai Haitong Keeps Their Buy Rating on Laekna, Inc. (2105)

TipRanksJun 17 20:45 ET · Ratings

US$527 million! LaiKe Pharma (02105) targets a golden opportunity and rises to NewCo 2.0.

Should Vasque Bio subsequently enter into a strategic partnership or acquisition transaction involving LAE118, LaiKai shall be entitled to receive additional milestone payments, up to 50% of the value of such strategic transaction.

Zhitong FinanceJun 10 20:37 ET

HKEX Announcement Insights | China Software International: Signs RMB 1 billion high-end AI computing equipment sales agreement to accelerate commercialization of computing power business

China Software International: Signed a RMB 1 billion sales agreement for high-end AI computing equipment to accelerate the commercialization of its computing power business; XtalPi Holdings entered into a strategic AI drug discovery partnership exceeding USD 400 million with a globally renowned pharmaceutical company to develop novel oral drugs targeting GPCRs…

Zhitong FinanceJun 9 20:59 ET